Claims for Patent: 7,404,956
✉ Email this page to a colleague
Summary for Patent: 7,404,956
| Title: | Immunoglobulin chimeric monomer-dimer hybrids |
| Abstract: | The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention. |
| Inventor(s): | Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low |
| Assignee: | Bioverativ Therapeutics Inc |
| Application Number: | US10/841,250 |
Details for Patent 7,404,956
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bioverativ Therapeutics, Inc. | ALPROLIX | coagulation factor ix (recombinant), fc fusion protein | For Injection | 125444 | March 28, 2014 | 7,404,956 | 2024-05-06 |
| Bioverativ Therapeutics, Inc. | ALPROLIX | coagulation factor ix (recombinant), fc fusion protein | For Injection | 125444 | February 18, 2016 | 7,404,956 | 2024-05-06 |
| Bioverativ Therapeutics, Inc. | ALPROLIX | coagulation factor ix (recombinant), fc fusion protein | For Injection | 125444 | July 14, 2016 | 7,404,956 | 2024-05-06 |
| Bioverativ Therapeutics, Inc. | ELOCTATE | antihemophilic factor (recombinant), fc fusion protein | For Injection | 125487 | June 06, 2014 | 7,404,956 | 2024-05-06 |
| Bioverativ Therapeutics, Inc. | ELOCTATE | antihemophilic factor (recombinant), fc fusion protein | For Injection | 125487 | January 27, 2017 | 7,404,956 | 2024-05-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch